肿瘤细胞治疗研究
英文原题：B Cell Aplasia Following CAR T Cell Therapy: Incidence, Kinetics, Prognostic Implications, and Clinical Management.
B细胞再生障碍（BCA），即循环中CD19阳性B细胞的持续耗竭，是抗CD19嵌合抗原受体（CAR）T细胞治疗标志性的在靶脱瘤效应。
B细胞再生障碍(BCA)，即循环中CD19阳性B细胞的持续耗竭，是抗CD19嵌合抗原受体(CAR)T细胞疗法标志性的在靶、脱肿瘤后果。尽管BCA在所有获批的CAR T细胞产品及所有有应答患者中均有发生，但其作为一种独立的临床和生物学现象尚未得到系统综述。本综述综合了B细胞急性淋巴细胞白血病(B-ALL)、大B细胞淋巴瘤、滤泡性淋巴瘤、套细胞淋巴瘤和慢性淋巴细胞白血病领域的里程碑试验与真实世界队列数据，以描述BCA发生率、恢复动力学、预后意义和管理启示。抗BCMA产品的作用机制根本不同，其耗竭浆细胞而非B细胞前体，故被有意排除在本综述之外。在已报告的队列中，所有应答者均观察到BCA，而无应答者始终没有BCA，使其成为CAR T细胞活性的可靠药效学标志物。其预后意义具有疾病特异性：在淋巴瘤中，BCA恢复不预测复发，且无论是否持续存在再生障碍，均可实现持久缓解；在B-ALL中，六个月内早期BCA恢复是CD19阳性复发的强有力独立预测因子，而持续性BCA与持续缓解相关。CD19阴性抗原逃逸复发更常发生于BCA完整且输注前肿瘤负荷较高的情况下。将BCA动力学与第28天和第3个月时的骨髓下一代测序微小残留病评估相结合，构成了目前可用的最强大的输注后风险分层框架。BCA在机制上与低丙种球蛋白血症相分离：IgM快速且显著下降，IgA下降较慢，而IgG——由CD19阴性长寿命浆细胞维持——是保留最完好的同种型。尚未建立B细胞计数阈值，低于该阈值时低丙种球蛋白血症才具有临床意义。提出了基于证据的IVIG替代阈值，尽管尚无随机试验数据支持这些阈值，这代表着一个需要前瞻性研究的关键空白。
B cell aplasia (BCA), the sustained depletion of circulating CD19-positive B cells, is the defining on-target, off-tumor consequence of anti-CD19 chimeric antigen receptor (CAR) T cell therapy. Despite its occurrence across all approved CAR T cell products and all responding patients, BCA has not been systematically reviewed as a standalone clinical and biological phenomenon. This review synthesizes data from landmark trials and real-world cohorts across B cell-acute lymphoblastic leukemia (B-ALL), large B cell lymphoma, follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia to characterize BCA incidence, recovery kinetics, prognostic significance, and management implications. Anti-BCMA products, which mechanism of action differs fundamentally, depleting plasma cells rather than B cell precursors, are intentionally excluded from this review. BCA is observed in all responders and is consistently absent in non-responders across reported cohorts , making it a reliable pharmacodynamic marker of CAR T cell activity. Its prognostic significance is disease-specific: in lymphoma, BCA recovery does not predict relapse and durable remission is achievable independent of sustained aplasia; in B-ALL, early BCA recovery within six months is a robust independent predictor of CD19-positive relapse, while persistent BCA correlates with sustained remission. CD19-negative antigen-escape relapse occurs preferentially in the presence of intact BCA and high pre-infusion tumor burden. Combining BCA kinetics with bone marrow next-generation sequencing minimal residual disease assessment at day 28 and month 3 constitutes the most powerful post-infusion risk-stratification framework currently available. BCA is mechanistically dissociated from hypogammaglobulinemia: IgM declines rapidly and profoundly, IgA more slowly, while IgG-maintained by CD19-negative long-lived plasma cells-is the most preserved isotype. No B cell count threshold below which hypogammaglobulinemia becomes clinically significant has been established. Evidence-informed IVIG replacement thresholds are proposed, though no randomized trial data exist to support them, representing a critical gap requiring prospective investigation.
MEMBER ACCOUNT
登录成功会直接打开下一页。
